Follow Us:
Monday, August 08, 2022

Ranbaxy hails US court ruling on Valcyte patent

The Ranbaxy spokesperson declined to comment on the company's marketing plans after the ruling of the court.

Written by Agencies | New Delhi |
October 16, 2009 3:29:20 pm

Ranbaxy laboratories welcomed a ruling by a US district court that said the company’s generic version of anti-viral drug Valcyte did not infringe Swiss pharma firm Roche’s patent.

“We welcome the positive development,” a Ranbaxy spokesperson said.

According to reports,the District Court of New Jersey has ruled that Ranbaxy’s generic version did not infringe Roche’s patented crystalline valganciclovir,the active ingredient in anti-viral drug Valcyte. The court,however,held Roche’s patent on the product as valid.

Ranbaxy had filed an Abbreviated New Drug Application (ANDA) on amorphous form of valganciclovir with the US Food and Drug Administration (FDA) in 2006. This was challenged by Roche saying the amorphous form of valganciclovir would change to crystalline form and,thus,will infringe the patent.

Subscriber Only Stories
Road to 2024 | Droupadi Murmu at Raisina Hill: BJP may run into some bumpsPremium
Nitish Kumar’s shuffle of 3 C cards: A tale of  his flip-flop-flips...Premium
ExplainSpeaking: What RBI’s surveys tell about India’s economyPremium
What Opposition states want: More IAS officers, MSP guarantee, GST exempt...Premium

The Ranbaxy spokesperson declined to comment on the company’s marketing plans after the ruling of the court.

TWO IS ALWAYS BETTER | Our two-year subscription package offers you more at less

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest News Archive News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
First published on: 16-10-2009 at 03:29:20 pm

Featured Stories